Will 10x Genomics' (TXG) Role in ASTRA Shift Its Competitive Edge in Precision Oncology?

• On November 18, 2025, the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan announced the launch of the Asia-Pacific Spatial Translational Research Alliance (ASTRA), a multi-country initiative to create a comprehensive pan-cancer spatial atlas using 10x Genomics' Xenium spatial platform, to map cancer and immune cell interactions across 2,000 tumor samples.
• This collaboration highlights the increasing adoption of 10x Genomics’ technology in major global research efforts and its growing influence in precision oncology across the Asia-Pacific region.
• We’ll examine how 10x Genomics’ involvement in this large-scale international cancer research initiative updates the company’s long-term investment narrative.

Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.

10x Genomics Investment Narrative Recap

To be a shareholder in 10x Genomics, you need to believe in sustained growth of precision medicine and single-cell analysis, as well as broad adoption of advanced spatial biology platforms. While the new ASTRA cancer atlas project highlights demand for 10x’s technology in a key growth region, the announcement itself does not materially change the near-term catalyst of broad adoption of newly launched consumables, nor does it alleviate the persistent risk from tightening global research budgets and weak capital spending.

Of recent announcements, the October 2025 launch of the Chromium Flex assay stands out for enabling scalable, high-throughput single-cell research. This product is positioned to address the very adoption and volume growth that serve as the short-term catalyst for revenue expansion, reinforcing 10x’s leadership as more customers transition to affordable solutions for precision genomics at scale.

By contrast, investors should pay special attention to…

Read the full narrative on 10x Genomics (it's free!)

10x Genomics' outlook anticipates $688.4 million in revenue and $97.8 million in earnings by 2028. This projection is based on a 2.2% annual revenue growth rate and an increase in earnings of $182.4 million from current earnings of -$84.6 million.

Uncover how 10x Genomics' forecasts yield a $15.86 fair value, in line with its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community range from US$6.47 to US$23.59 per share. With global research funding top of mind, readers can see just how differently market participants interpret the company's future potential.

Explore 6 other fair value estimates on 10x Genomics - why the stock might be worth less than half the current price!

Build Your Own 10x Genomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com